WEBVTT

1
00:00:00.040 --> 00:00:00.760
<v Speaker 1>H Hi Tracy.

2
00:00:00.920 --> 00:00:04.599
<v Speaker 2>Hello everyone. I'm Valerie Bowling and I'm the executive director

3
00:00:04.639 --> 00:00:08.080
<v Speaker 2>of the conference Forum. I'm with the director of DEFARM,

4
00:00:08.240 --> 00:00:11.599
<v Speaker 2>Tracy Kimball, and today we're going to talk about AI

5
00:00:12.000 --> 00:00:16.359
<v Speaker 2>and we're doing a just a brief series of really

6
00:00:16.399 --> 00:00:19.160
<v Speaker 2>like vignettes on what you can expect at the fifteenth

7
00:00:19.199 --> 00:00:20.199
<v Speaker 2>annual DEFARM.

8
00:00:20.480 --> 00:00:24.079
<v Speaker 1>This is a celebration year for US. DEFARM was launched.

9
00:00:23.960 --> 00:00:27.359
<v Speaker 2>Obviously fifteen years ago, and it was launched really with

10
00:00:27.600 --> 00:00:30.320
<v Speaker 2>the idea of how can we disrupt the way we

11
00:00:30.399 --> 00:00:33.960
<v Speaker 2>do clinical research to make it far more efficient, focusing

12
00:00:34.000 --> 00:00:38.719
<v Speaker 2>on automation ultimately focusing of course on the patient, how

13
00:00:38.719 --> 00:00:41.479
<v Speaker 2>to reduce that burden, how to be better partners to

14
00:00:41.600 --> 00:00:44.039
<v Speaker 2>our sites and reduce the bird to them as well.

15
00:00:44.520 --> 00:00:47.600
<v Speaker 2>So the ultimate really the description, if you will, of

16
00:00:47.600 --> 00:00:50.719
<v Speaker 2>the definition of disruption is how do you make something

17
00:00:51.200 --> 00:00:54.399
<v Speaker 2>more convenient and less expensive in its simplest form, if

18
00:00:54.439 --> 00:00:56.880
<v Speaker 2>you will. So how do we actually apply that to

19
00:00:57.679 --> 00:01:00.960
<v Speaker 2>clinical research? And that's what DEFARM is about. So we

20
00:01:01.119 --> 00:01:05.159
<v Speaker 2>focus on how can we bring forward innovation, new ideas,

21
00:01:05.359 --> 00:01:09.200
<v Speaker 2>how can we leap frog these into execution and inspire

22
00:01:09.319 --> 00:01:13.120
<v Speaker 2>the clinical trial operations community. So it is about ultimately

23
00:01:13.200 --> 00:01:17.200
<v Speaker 2>as well modernizing way we do clinical trials. So we

24
00:01:17.319 --> 00:01:19.959
<v Speaker 2>have a bar to reach every year, of course, and

25
00:01:20.560 --> 00:01:23.959
<v Speaker 2>somehow we do it and Tracy leads the way on

26
00:01:24.319 --> 00:01:26.400
<v Speaker 2>doing that. So today we want to talk about AI

27
00:01:27.000 --> 00:01:30.480
<v Speaker 2>because obviously AI is the probably the hugest topic going.

28
00:01:30.680 --> 00:01:32.159
<v Speaker 2>But what does it really mean? What does it really

29
00:01:32.159 --> 00:01:35.079
<v Speaker 2>do for you? What's real, what's annoying, what's not really

30
00:01:35.079 --> 00:01:38.920
<v Speaker 2>going to help you? That's important and we know that

31
00:01:39.079 --> 00:01:41.719
<v Speaker 2>AI is going to be in everything. So for example,

32
00:01:41.760 --> 00:01:44.239
<v Speaker 2>I was reading an article the other day about how

33
00:01:44.599 --> 00:01:47.680
<v Speaker 2>AI will be in refrigerators and toasters and everyone's going

34
00:01:47.719 --> 00:01:49.400
<v Speaker 2>to know how many times you open that fridge and

35
00:01:50.120 --> 00:01:53.680
<v Speaker 2>turn that toaster on. Anyhow, it's our future and it's

36
00:01:53.760 --> 00:01:56.200
<v Speaker 2>huge and it's everywhere. But what is it really doing

37
00:01:56.200 --> 00:01:59.079
<v Speaker 2>for us in clinical trial operations? And what can we

38
00:01:59.120 --> 00:02:03.079
<v Speaker 2>bring forward that will actually be useful and helpful in

39
00:02:03.120 --> 00:02:06.319
<v Speaker 2>the work that you're doing. So Tracy, with that, I

40
00:02:06.359 --> 00:02:08.280
<v Speaker 2>want to ask you if you can tell us a

41
00:02:08.319 --> 00:02:12.120
<v Speaker 2>little bit about what we can expect for AI this year.

42
00:02:13.159 --> 00:02:15.759
<v Speaker 1>Yeah. Absolutely, I'd like to talk about the.

43
00:02:15.680 --> 00:02:18.159
<v Speaker 3>Three sessions in particular, there are many sessions, as you

44
00:02:18.199 --> 00:02:21.199
<v Speaker 3>said that we'll be talking about how clinical operations. Teams

45
00:02:21.280 --> 00:02:26.520
<v Speaker 3>are integrating EAI machine learning throughout clinical trial operations to

46
00:02:26.560 --> 00:02:29.159
<v Speaker 3>do just as what we've been talking about, automating and

47
00:02:29.280 --> 00:02:30.840
<v Speaker 3>accelerating clinical trials.

48
00:02:31.120 --> 00:02:34.599
<v Speaker 1>But we are so fortunate to have Don Tampy, who

49
00:02:34.719 --> 00:02:38.520
<v Speaker 1>is the head of Global Introbated Clinical Data from Mark,

50
00:02:39.319 --> 00:02:44.960
<v Speaker 1>unveiling their strategy for automating clinical trial operations. Don was

51
00:02:45.039 --> 00:02:46.879
<v Speaker 1>just tasked with this with this.

52
00:02:46.879 --> 00:02:49.960
<v Speaker 3>Mandate and it is a timely mandate for them that

53
00:02:50.039 --> 00:02:53.319
<v Speaker 3>they want to accelerate, and he will be presenting on

54
00:02:53.680 --> 00:02:59.039
<v Speaker 3>their initial validated strategy along with the initial roadmap.

55
00:02:58.759 --> 00:03:00.639
<v Speaker 1>They have and early readouts.

56
00:03:00.840 --> 00:03:03.560
<v Speaker 3>The exciting disruptive thing that will be happening at Defarmers

57
00:03:03.639 --> 00:03:05.280
<v Speaker 3>will be using AI through that.

58
00:03:05.199 --> 00:03:07.960
<v Speaker 1>Session to take the feedback.

59
00:03:08.000 --> 00:03:10.280
<v Speaker 3>Then people will that our Defarm audience will be able

60
00:03:10.280 --> 00:03:14.159
<v Speaker 3>to give Don throughout the session, analyze that feedbacks and

61
00:03:14.639 --> 00:03:17.599
<v Speaker 3>report back on that during the session to kind of

62
00:03:17.639 --> 00:03:22.800
<v Speaker 3>see how industry or our audience thinks that perhaps.

63
00:03:22.560 --> 00:03:25.159
<v Speaker 1>The pass forward should include X, Y and D. So

64
00:03:25.520 --> 00:03:27.080
<v Speaker 1>it's a very exciting session.

65
00:03:27.199 --> 00:03:31.000
<v Speaker 3>We are delighted to have DONA and Mark representative bring

66
00:03:31.039 --> 00:03:33.680
<v Speaker 3>this session to DEFARM. So that's day one, the warning

67
00:03:33.719 --> 00:03:36.840
<v Speaker 3>of day one, and that Day two, we have to

68
00:03:36.879 --> 00:03:41.080
<v Speaker 3>senior leadership AI sessions. The first one looking at generative

69
00:03:41.159 --> 00:03:45.439
<v Speaker 3>AI from the perspective of lining aligning your resources with ROI.

70
00:03:46.000 --> 00:03:49.840
<v Speaker 3>We have an excellent panel with Barry Call from Regeneron

71
00:03:49.960 --> 00:03:50.960
<v Speaker 3>as our moderator.

72
00:03:51.439 --> 00:03:53.879
<v Speaker 1>We have Faisal Koon who spoke last.

73
00:03:53.759 --> 00:03:57.520
<v Speaker 3>Year at DEFARM as a panelist from nov norns, Suba

74
00:03:57.719 --> 00:04:02.159
<v Speaker 3>Matt Hoven who is the VP of AI, and M

75
00:04:02.360 --> 00:04:06.000
<v Speaker 3>L within R and d Cross Busor and then a

76
00:04:06.159 --> 00:04:10.800
<v Speaker 3>new a new leader of these NASA from Insight who's

77
00:04:10.840 --> 00:04:14.520
<v Speaker 3>the head of their AI innovations institutes, and they'll really

78
00:04:14.520 --> 00:04:17.079
<v Speaker 3>be looking at use cases where it's being used, the

79
00:04:17.160 --> 00:04:21.240
<v Speaker 3>impact that we're seeing on you know, costs, timelines, speed,

80
00:04:21.839 --> 00:04:25.480
<v Speaker 3>efficiencies as well as kind of thinking about it from

81
00:04:25.519 --> 00:04:29.879
<v Speaker 3>the perspective of you know, impacts and you know, what

82
00:04:30.000 --> 00:04:32.000
<v Speaker 3>kind of talent will you need to have in house

83
00:04:32.480 --> 00:04:35.839
<v Speaker 3>to to really capitalize on genit of AI.

84
00:04:36.680 --> 00:04:39.439
<v Speaker 1>And then we'll go from that session right into another

85
00:04:39.560 --> 00:04:43.639
<v Speaker 1>AI session that's looking at a gentic AI and what

86
00:04:43.759 --> 00:04:48.879
<v Speaker 1>the potential how it can potentially revolutionize trial operations.

87
00:04:48.360 --> 00:04:50.800
<v Speaker 3>Level setting sort of on you know what people are

88
00:04:50.839 --> 00:04:55.560
<v Speaker 3>seeing as the you know the definitions of agentic AI

89
00:04:56.240 --> 00:05:01.040
<v Speaker 3>agentic AI architecture and where it's being used, the impact

90
00:05:01.399 --> 00:05:04.079
<v Speaker 3>and that session also has an incredible group of folks

91
00:05:04.079 --> 00:05:04.759
<v Speaker 3>in discussing.

92
00:05:05.040 --> 00:05:05.879
<v Speaker 1>We have Angela de.

93
00:05:05.920 --> 00:05:10.759
<v Speaker 3>Ludegaws, the head of Global Study Operation at MJAM, as

94
00:05:10.759 --> 00:05:14.279
<v Speaker 3>well as panelists that include Sid Hyder who is from

95
00:05:14.519 --> 00:05:18.959
<v Speaker 3>murp AND's Room, the head of their business ITAA Partnerships,

96
00:05:19.480 --> 00:05:22.800
<v Speaker 3>u su Bidalcaid who's the head of the AI Research

97
00:05:22.879 --> 00:05:26.639
<v Speaker 3>Center at Gilead, and Henry Way from Regeneral's the head

98
00:05:26.639 --> 00:05:30.279
<v Speaker 3>of development Innovation. So three really strong, exciting sessions looking

99
00:05:30.279 --> 00:05:32.360
<v Speaker 3>at AI. So very nice job.

100
00:05:32.439 --> 00:05:35.839
<v Speaker 2>And so we have September sixteenth and seventeenth at the

101
00:05:35.879 --> 00:05:38.040
<v Speaker 2>Low's Philadelphia Hotel. I'm happy to say we have the

102
00:05:38.040 --> 00:05:40.279
<v Speaker 2>whole hotel Lasty we only had part of it, so

103
00:05:40.360 --> 00:05:41.480
<v Speaker 2>we have much more space.

104
00:05:41.639 --> 00:05:42.920
<v Speaker 1>And the day before.

105
00:05:42.759 --> 00:05:46.519
<v Speaker 2>DFARM, we're also running a conference called Partnerships with Sites,

106
00:05:46.560 --> 00:05:49.519
<v Speaker 2>as well as our CRACO event, which is also having

107
00:05:49.560 --> 00:05:52.600
<v Speaker 2>an anniversary year. It's its tenth year, and that's Clinical

108
00:05:52.639 --> 00:05:54.800
<v Speaker 2>Research as a Care Option and they're going to share

109
00:05:54.839 --> 00:05:57.519
<v Speaker 2>the same networking those two events because they have a

110
00:05:57.519 --> 00:06:00.439
<v Speaker 2>lot of overlap. All right, So Tracy, thank you so much,

111
00:06:00.480 --> 00:06:04.519
<v Speaker 2>and obviously will continue our series and looking at different

112
00:06:04.519 --> 00:06:07.439
<v Speaker 2>sections of deforming, what it will do and how it

113
00:06:07.480 --> 00:06:09.480
<v Speaker 2>will help folks in clinical trial operations.

114
00:06:09.519 --> 00:06:11.600
<v Speaker 1>So thanks so much, thanks